Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
An ongoing dialogue on HIV/AIDS, infectious diseases,
February 13th, 2013
Medication Adherence: The Final Frontier
Treatment of HIV has become so amazingly effective that when it fails, it’s no overstatement to say that it’s usually because the patient is not taking the medications. There are all kinds of provider-related reasons for this — inadequate patient education, prescribing and dispensing errors, failure to address language or education deficits — but here I want to focus on the patient-related causes.
In other words, on non-adherence.
(This used to be called “non-compliance.” That term has become un-PC; for some reason non-adherence is viewed as nicer. Please explain.)
Non-adherence in HIV care comes in a variety of flavors, including:
- Denial — “I feel fine, so why should I take those medicines? Yes, you tell me I have HIV, but I don’t really believe it’s a dangerous condition, or even that I have it, since as I said, I feel fine.“
- Stigma — “I won’t take those medications because each dose reminds me that I have HIV. And that makes me feel awful again and again, so until we can solve that problem, no chance I’m taking HIV meds.”
- Chaos — “You say I should take these medications, but how can I do so when my life is so horribly complicated because of family issues [or addiction or other medical problems or psychiatric disease or homelessness or …], so I’m going to ignore that recommendation to go on meds, and take my chances.”
- Deceit — “I’m taking the medications exactly as you prescribed. I rarely, if ever, miss a dose. Yes, my pharmacy told you I have not refilled my one-month supply of meds since 2009, but that doesn’t change the fact that I’m taking the medications exactly as prescribed. I told you that already.”
- Hypersensitivity — “I get side effects to everything. Literally everything. So I might leave the office today with a prescription, but I won’t fill it, because it will make me sick. Look, when I told you this, and you said that all medicines might have side effects, you proved my point.”
- Sicko — “Sure, I’ll take the medications if insurance covers the cost. But I lost my insurance, so rather than investigate getting on COBRA or an AIDS Drug Assistance Plan (ADAP) or some other program to keep me covered, I just stopped my meds. And that was 6 months ago.”
I’m sure there are others, but this list covers most of them. Note that these are not mutually exclusive, and some of the knottiest adherence problems come when more than one of the above is operative. Note also that I’m not counting the people who simply disappear from care — the “engagement in care” or “linkage” issue — which is a huge problem and responsible for lots of the drop-off in the infamous treatment cascade.
But the multifactorial nature of poor adherence is one reason why studies of adherence interventions so often have negative results. How can any single intervention address all of these factors?
Another reason for the negative studies is that the vast majority of patients do take their antivirals correctly — and this good med-taking behavior is probably especially common among those with the wherewithal to sign an informed consent for a clinical study. Most of these folks don’t need any help at all, so the intervention looks no better than the control; this study is an excellent example.
Yet if we can’t identify ahead of time the small fraction of our patients who will be non-adherent — and study after study says we can’t — how can we target our interventions to the people who need them the most?
Paul E. Sax, MD
Learn more about HIV and ID Observations.
- Should Doctors Still Be Allowed to Wear White Coats? You Decide (43)
- Are ID Doctors the Worst Dressed Specialists? (39)
- Which Infectious Diseases Do We Fear Too Much? Which Not Enough? (33)
- Are Fluoroquinolones Really More Dangerous Than Other Antibiotics? (30)
- How to Make the Flu Vaccine More Popular, Warts and All (24)
- Twelve Zika Questions, One ID Doctor’s Answers (Sort Of)
- Here’s an Idea: Justify Your Specialty’s (Low) Relative Salary Using Moral Superiority
- Elbasvir/Grazoprevir Combination Pill for HCV a Welcome New Option — With a Few Buts
- IV and Injectable HIV Treatments Are Much Discussed — But Won’t Be Here Anytime Soon
- Why ID/HIV Specialists Rank Last in MD Salaries
Subscribe to HIV and ID Observations via Email
- Glucocorticoids Are Not the Answer for HIV-Associated Cryptococcal Meningitis
- Revised Guidelines on Tuberculosis Testing in the U.K.
- Whole-Genome Sequencing Detects Nosocomial Legionellosis
- Figuring Out When to Stop Anti-CMV Prophylaxis After Lung Transplantation
- Is Bone Loss After Initiating ART Mediated by Immune Reconstitution?
Physician's First WatchToday's breaking medical news
- Abacavir AIDS aids clinical care antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff CROI cure darunavir dolutegravir efavirenz elvitegravir etravirine FDA HCV hepatitis C HIV HIV testing ID Learning Unit Infectious Diseases influenza lamivudine Link-o-Rama lyme disease Massachusetts MRSA Patient Care PEP Policy PrEP prevention primary care raltegravir Research resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir vaccination